Cutaneous melanoma · line 2 · Imatinib (KIT-mutant mucosal/acral melanoma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-IMATINIB-KIT-MELANOMA |
| ID | IND-MELANOMA-2L-KIT-IMATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CARVAJAL-KIT-MELANOMA-2013 SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Niche standard-track option for KIT-mutant mucosal/acral melanoma — small subset (~15-20% of mucosal/acral, which is ~5% of all melanoma) but high-value because oral, low-tox, accessible (generic imatinib). Prioritized FIRST in algorithm if KIT-actionable mutation present. Off-label use in UA — MDT documentation required. ESCAT IIA per ESMO molecular targets framework.
Used By
Algorithms
ALGO-MELANOMA-METASTATIC-2L- ALGO-MELANOMA-METASTATIC-2L